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OBJECTIVE—Aggregation of human amylin/islet amyloid
polypeptide (hA/hIAPP) into small soluble -sheet–containing
oligomers is linked to islet -cell degeneration and the pathogen-
esis of type 2 diabetes. Here, we used tetracycline, which
modiﬁes hA/hIAPP oligomerization, to probe mechanisms
whereby hA/hIAPP causes diabetes in hemizygous hA/hIAPP-
transgenic mice.
RESEARCH DESIGN AND METHODS—We chronically
treated hemizygous hA/hIAPP transgenic mice with oral tetracy-
cline to determine its effects on rates of diabetes initiation,
progression, and survival.
RESULTS—Homozygous mice developed severe spontaneous
diabetes due to islet -cell loss. Hemizygous transgenic animals
also developed spontaneous diabetes, although severity was less
and progression rates slower. Pathogenesis was characterized by
initial islet -cell dysfunction followed by progressive -cell loss.
Islet amyloid was absent from hemizygous animals with early-
onset diabetes and correlated positively with longevity. Some
long-lived nondiabetic hemizygous animals also had large islet-
amyloid areas, showing that amyloid itself was not intrinsically
cytotoxic. Administration of tetracycline dose-dependently ame-
liorated hyperglycemia and polydipsia, delayed rates of diabetes
initiation and progression, and increased longevity compared
with water-treated controls.
CONCLUSIONS—This is the ﬁrst report to show that treating
hA/hIAPP transgenic mice with a modiﬁer of hA/hIAPP misfold-
ing can ameliorate their diabetic phenotype. Fibrillar amyloid
was neither necessary nor sufﬁcient to cause diabetes and indeed
was positively correlated with longevity therein, whereas early-
to mid-stage diabetes was associated with islet -cell dysfunction
followed by -cell loss. Interventions capable of suppressing
misfolding in soluble hA/hIAPP oligomers rather than mature
ﬁbrils may have potential for treating or preventing type 2
diabetes. Diabetes 59:161–171, 2010
T
ype 2 diabetes is a chronic hyperglycemic disor-
der caused by defective action and/or secretion
of insulin, which manifests with complications
that ultimately cause most of its morbidity and
mortality. It is also an amyloidosis, since it is accompanied
by amyloid deposits in regions of tissue degeneration and
-cell loss in the islets of Langerhans (1,2). These deposits
(3) comprise mainly ﬁbrillar aggregates of a 37–amino acid
monomer, human amylin (hA)/islet amyloid polypeptide
(hIAPP) (4,5) (the term hA/hIAPP has been used to reﬂect
the two names commonly used for this peptide hormone),
which is secreted from the -cells.
Islet amyloid is associated with substantial reductions in
relative -cell mass in type 2 diabetes (on average 60%),
probably due to increased apoptosis compared with obese
and lean nondiabetic humans (2). An inability to adap-
tively compensate -cell mass in type 2 diabetes has been
postulated to lead to or cause an absolute insulin deﬁ-
ciency over time with a resulting requirement for insulin
replacement therapy in affected subjects (1).
Several lines of evidence now provide compelling sup-
port for the idea that processes associated with hA/hIAPP
aggregation contribute to -cell degeneration. First, in
vitro studies with synthetic hA/hIAPP preparations show
that ﬁbrillar structures are generated spontaneously
through self-association of monomers into protoﬁbrils and
higher-order ﬁbrils (6). Cytotoxic hA/hIAPP preparations
contain few preformed ﬁbrils but undergo time-dependent
aggregation into soluble -conformers (7). -Cell toxicity
evoked by aggregating extracellular hA/hIAPP occurs
through an apoptotic mechanism (8,9) mediated via a
pathway comprising initial activation of a membrane-
bound Fas/FasL/FADD/caspase-8 complex (10) followed
by a three-pronged downstream cascade comprising
c-Jun NH2-terminal protein kinase 1/cJun (11), activat-
ing transcription factor 2/p38 mitogen-activated protein
kinase (12), and p53/p21
WAF1/CIP1 (9) that leads ulti-
mately to activation of caspase-3 (13). In addition,
parallel amylin-mediated activation of endoplasmic re-
ticulum stress–related pathways may contribute to islet
-cell degeneration (14).
Second, associations between hA/hIAPP aggregation
and decreased -cell mass have been reported from in vivo
studies (15–19) in several murine transgenic models of
hA/hIAPP-mediated diabetes. By contrast, mA/mIAPP mol-
ecules do not aggregate, so diabetic phenotypes in hA/
hIAPP transgenic mice develop in a background devoid of
amyloid formed by mA/mIAPP. Obese hA/hIAPP trans-
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ﬁndings of human type 2 diabetes, showing nonketotic
hyperglycemia, amyloid deposition, and decreased -cell
mass, possibly via increased apoptosis (18).
These data support a hypothesis that hA/hIAPP aggre-
gation could mediate -cell failure in type 2 diabetes.
However, the signiﬁcance of mature amyloid ﬁbrils in the
pathogenesis of this process is still uncertain, as is
whether hA/hIAPP-mediated cytotoxicity can be abro-
gated by in vivo treatment with amylin-binding com-
pounds. Peptide-based analogs that bind amyloid-forming
structural motifs within hA/hIAPP have reportedly inhib-
ited aggregation of synthetic hormone in vitro, with con-
comitant suppression of cytotoxicity in cultured -cells
(20), but in vivo efﬁcacy of this therapeutic approach has
yet to be reported.
Here, we have generated lines of hA/hIAPP transgenic
mice that spontaneously develop diabetes. Phenotypes
vary from early-onset diabetes without microscopically
detectable amylin aggregates to late-onset diabetes with
microscopic amyloid deposits. Diabetes pathogenesis and
progression in hemizygous animals occurs primarily
through islet -cell dysfunction with subsequent -cell
loss. Both onset and progression were signiﬁcantly inhib-
ited by chronic treatment with tetracycline, an antibiotic
that interacts with aggregates of proteins implicated in
amyloid-related diseases (21–23).
RESEARCH DESIGN AND METHODS
Ethics approval. Experimental protocols were approved by the University of
Auckland Animal Ethics Committee and performed in accordance with the
New Zealand Animal Welfare Act (1999).
Materials. Chemicals and kits were from Roche Applied Biosciences, Invitro-
gen, Life Technologies/BRL, or Sigma and were of analytical grade or better,
unless stated otherwise.
Generation of hA/hIAPP transgenic mice. The hA/hIAPP transgene (sup-
plemental Fig. S1A [available at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-0548/DC1]) was constructed from PCR-derived fragments
using the following primer pairs: RIP5 (GAAAGACTCGAGGATCCCCCAAC
CAC) and RIP3 (CAGGGCCATGGTGGAACAATGACC), hAMY5 (GAAGC
CATGGGCATCCTGAAGCTGCAAGTA) and hAMY3 (GTCATGTGCACCT
AAAGGGGCAAGTAATTCA), hALB5 (GTGTGTTTCATCGATATGCACGTAA
GAAA) and hALB3 (CAACCTCAAGCTTGTCTGGGCAAGGG), hGAPDH5
(GGAGTAAGCTTCCTGGACCACCAGCCCC), and hGAPDH3 (GTGCGA
GTCT-AGACTTCCTCCACCTGTCA). It was introduced into the genome by
pronuclear injection (24).
Northern analysis. RNA was extracted from liquid nitrogen snap-frozen
tissues using QIAGEN RNeasy Midi Kits according with the rotor-stator tissue
disruption (Ultra-Turrax T8; IKA-Werke, Germany). Total RNA (20 g) was
denatured and transferred to nylon membranes with 20 SSC (25) and
hybridized to
32P-labeled probes (26) at 65°C overnight. Intensities of mRNA
bands corresponding to hA/hIAPP and mA/mIAPP were not directly compared
as experimental conditions differed (supplemental Fig. S1A and B).
Animal studies. Mice were fed ad libitum with Diet 86 (Tegel NRM,
Auckland, Zealand), a dry-pelleted natural-ingredient diet with 3% fat. Blood
glucose levels were determined in tail vein blood (Advantage II; Roche) and
diabetes deﬁned when concentrations were 11 mmol/l on two consecutive
weekly readings. For survival studies, we applied an agreed euthanasia
surrogate end point for death, consistent with current ethical practice.
Euthanasia was performed in the following circumstances: after 20% loss of
maximum body weight, if signiﬁcant lethargy developed, following loss of
exploratory behavior with increasing relative immobility, failure to groom,
or any other signs of overt distress. Infection or malignancy were also
accepted as indications for euthanasia.
Intraperitoneal insulin and glucose tolerance tests. Mice undergoing
intraperitoneal insulin tolerance tests (ITTs) were typically fasted for 6 h.
Thereafter, actrapid (0.5 mIU/g body wt; Novo Nordisk) was injected intra-
peritoneally in conscious animals (29 G needle). Glucose levels were mea-
sured before injection and at indicated times postinjection. For
intraperitoneal glucose tolerance tests (GTTs), mice were overnight fasted
(16–18 h) with free access to water. Glucose was administered (1 mg
glucose/g body wt) followed by tail blood sampling.
Blood and tissue extraction for hormone measurements. Cardiac punc-
ture blood (EDTA) was separated (3,000g, 4°C, 15 min). Pancreata were
excised and snap frozen (liquid nitrogen) and peptides extracted (homogeni-
zation, acid/ethanol) (27).
Hormone measurements. Murine insulin was determined in plasma, serum,
or pancreatic extracts by Ultrasensitive Mouse Insulin enzyme-linked immu-
nosorbent assay (ELISA) (Mercodia, Uppsala, Sweden) or rat/mouse insulin
ELISA (Linco). Pancreatic extracts were diluted (1:500 and 1:5,000) in PBS
(pH 7.4). Plasma hA/hIAPP was determined by ELISA (Linco) in plasma and
pancreatic extracts; mA/mIAPP was determined using our in-house
radioimmunoassay.
Pancreatic histochemistry and quantitative islet histomorphometry.
Pancreatic tissue was parafﬁn embedded, serially sectioned (5 m), and
stained with hematoxylin and eosin. On adjacent sections, Congo red (1%;
15–20 min, then saturated lithium carbonate, 30 s) and hematoxylin staining
were used to measure frequency and extent of islet amyloid (polarization
microscopy). Islet morphology and amyloid content were analyzed by a
single-blinded histologist who scored nine or more islets/animal. Pancreata
were sectioned at sufﬁcient levels (200 m apart) to ensure analysis of 9
(but generally 20–30) distinct islets/animal.
Immunohistochemistry. Representative sections were serially incubated
with guinea pig anti-insulin serum, donkey anti-guinea pig IgG–ﬂuorescein
isothiocyanate, rabbit anti-glucagon, and donkey anti-rabbit IgG–Texas Red
then counterstained with Congo red and reimaged to quantitate islet amyloid,
morphology, and insulin and glucagon cells. Alternatively, sections were
incubated with combined rabbit anti-glucagon and anti-somatostatin and
imaged by indirect avidin-biotin-peroxidase.
Chronic oral administration of tetracycline. Tetracycline was adminis-
tered orally via the drinking water in light-proof bottles either from the time
of weaning (21 days of age) or from diabetes onset in different studies, at ﬁnal
concentrations (0.03 mg/ml or 0.5 mg/ml in water, 18 mol  l
1  cm
1, milliQ;
Millipore) and fresh solutions constituted weekly. Polydipsia was deﬁned as
ﬂuid intake exceeding twice the average daily intake of the average nondia-
betic adult mouse. Controls comprising hemizygous male mice and nontrans-
genic littermates received milliQ water alone.
Statistical analysis. Data were analyzed using GraphPad Prism 4 (GraphPad
Software, San Diego, CA) and diabetes onset and survival using the Mantel-
Haenszel log-rank test and the Gehan-Breslow-Wilcoxon test. Correlation
analyses were performed using Pearson correlation with two-tailed hypothe-
ses. Descriptive variables were contrasted by one-way ANOVA with Tukey-
Kramer post hoc tests. Blood glucose and ﬂuid intake values were contrasted
using mixed models ﬁtted by restricted maximum likelihood (JMP 5.1; SAS
Institute). P values of 0.05 were considered signiﬁcant.
RESULTS
Human amylin/hIAPP transgenic mice spontaneously
developed diabetes. Transgenic animals were generated
within a FVB/N background (supplmentary Fig. S1). One
transgenic line, hereinafter designated as Line 13, had
integrated transgene copy numbers of 36 	 7 and 76 	 2
for hemizygous and homozygous animals, respectively
(data not shown).
Diabetes developed spontaneously and reproducibly in
both homozygous and hemizygous Line 13 male and
female mice, while nontransgenic littermates did not de-
velop hyperglycemia (Fig. 1). All subsequent studies were
performed in male animals (28,29). In homozygous mice,
diabetes developed in 100% of animals (n 
 6) by 41 days
and all were dead by 91 days (Fig. 1A). By comparison,
median values for time to diabetes onset and lifespan
within the hemizygous group were longer (175 and 272
days, respectively) compared with homozygous animals
(35 and 63 days, respectively). In addition, a second,
independent line (designated Line 20) generated with the
same construct and methods also developed spontaneous
diabetes (Fig. 1A). Thus, the diabetic phenotype was not
an artifact arising from insertional mutagenesis.
Intraperitoneal ITTs performed at 85 days showed that
hemizygous mice developed spontaneous diabetes within
a background of normal insulin sensitivity (Fig. 1B). Time
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between diabetes onset and death, showing that age did
not inﬂuence the rate of progression of diabetes once it
had begun (Fig. 1C).
Severity of diabetes progression was directly related
to pancreatic expression of amyloidogenic human
amylin. In homozygous mice, at an age where they were
glucose intolerant (30 days; intraperitoneal GTTs not
shown), plasma hA/hIAPP concentrations were 1.8-fold
higher than in hemizygous animals and 3.7-fold above
nontransgenic control mA/mIAPP concentrations (Table
1). Normal plasma insulin was maintained in homozygous
mice at 30 days despite a 72% reduction in pancreatic
insulin content. Thus, at a time point similar to the median
time to diabetes (35 days), substantial pancreatic insulin
depletion had occurred in homozygous transgenic mice
before a reduction in circulating insulin concentrations
was detectable. Interestingly, and by contrast, pancreatic
insulin concentrations in hemizygous animals were rela-
tively unchanged at a time point (183 days) similar to the
respective median onset time to diabetes (175 days).
These data indicated that an 2- to 2.5-fold increase in
expression of hA/hIAPP above endogenous and nonamy-
loidogenic mA/mIAPP in hemizygous animals was sufﬁ-
cient to evoke diabetes.
Amyloid deposition was dissociated from diabetes
and positively correlated with lifespan. To investigate
the relationship between amyloid deposition and diabetic
phenotype, islet amyloid area was quantitated microscopi-
cally. Of the diabetic hemizygous animal cohort examined,
there was a positive correlation between amyloid content
and lifespan in animals that had survived 220 days (44%
frequency, P  0.001) (Fig. 1D and Fig. 2, top two panels).
However, amyloid was rarely observed in terminally diabetic
animals killed at lifespans 220 days (49% frequency). As
expected, amyloid deposition was never observed in the
islets of nontransgenic animals (Fig. 2, middle panel). Inter-
estingly, some hemizygous animals remained nondiabetic
(7% frequency) but showed the presence of islet amyloid
(Fig. 1D and Fig. 2, second to bottom panel) with a similar
relationship between amyloid content and lifespan as ob-
served for diabetic hemizygous animals (P  0.05). Amyloid
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FIG. 1. Characterization of spontaneous diabetes in homozygous and hemizygous hA/hIAPP transgenic mice. A: Survival curves for two distinct
lines of hA/hIAPP transgenic mice that were generated by separate injections of the same construct in the FVB/N background: homozygous line
13 (‚, n  6); hemizygous line 13 (E, n  14); and hemizygous line 20 (ƒ, n  7). Closed symbols represent corresponding nontransgenic
littermates. B: Intraperitoneal insulin tolerance tests in hemizygous line 13 mice (E, n  11) versus nontransgenic littermates (F, n  6) at 85
days of age. Animals were fasted overnight (17 h) then injected with Actrapid (0.75 mIU/g body wt). Data are means  SE. C: Correlational
analysis between time to diabetes onset and time of diabetes onset to death in hemizygous line 13 mice (P  NS, n  19). D: Amyloid areas were
positively correlated with lifespan in diabetic water-treated (E, dashed line; n  14, R
2  0.78, P < 0.001) and nondiabetic hemizygous animals
(half-closed circles, n  4, R
2  0.95, P < 0.05). Arrows indicate animals with representative islets shown in Fig. 2.
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Line 13 mice analyzed (Fig. 2, bottom panel).
End-stage diabetes was characterized by selective
loss of -cells from the islets. Immunohistochemistry of
pancreatic islet sections using antisera to stain both - and
-cells showed that almost all the islet cells in terminally
diabetic homozygous and hemizygous mice were non–-
cells (Fig. 2). Glucagon staining also revealed a change in
-cell distribution from the physiological location at the
islet periphery to a more dispersed distribution throughout
diabetic islets, a substantive change in histomorphology
(Fig. 2). Taken together, these ﬁndings show that end-
stage diabetes in both homozygous and hemizygous ani-
mals was associated with islet -cell loss and altered islet
architecture. Consistent with these observations, plasma
insulin and amylin concentrations in terminally killed
homozygous and hemizygous animals were below the
limits of detection (data not shown). We also performed
studies for terminal deoxynucleotidyl transferase-medi-
ated dUTP nick-end labeling and caspase-3 activation in
islets from animals at different stages of diabetes, but rates
were not signiﬁcantly different between those from dia-
betic and control (nondiabetic) animals (results not
shown). These ﬁndings are consistent with the observa-
tion that although apoptosis is widespread in biology,
dying cells are seldom seen in situ because of their rapid
clearance by phagocytosis (30). They do not, however,
exclude the possibility that the sensitivity of the assays
used may not have been sufﬁcient to detect any differences
in numbers of rare apoptotic cells.
Chronic oral administration of tetracycline (0.03
mg/ml drinking water) from weaning improved glyce-
mic control and lifespan in hemizygous mice (study
1). We previously reported that tetracycline interacts with
amylin ﬁbrils based on evidence from thioﬂavin-T ﬂuores-
cence and radioprecipitation assays (31). Here, we provide
additional in vitro evidence for speciﬁc interactions between
tetracycline and hA/hIAPP by circular dichroism spectros-
copy (supplementary Fig. S2). In addition, to investigate
whether tetracycline might modulate indexes of aggregation-
evoked diabetes in vivo, hemizygous mice were randomly
assigned to groups that were administered either water alone
(control) or water containing 0.03 mg/ml tetracycline. Trans-
genic animals treated with tetracycline (0.03 mg/ml) devel-
oped diabetes with an apparently earlier median time to
onset (85 days, n 
 17) compared with those administered
water only (121 days, n 
 20), which is a difference that was
not signiﬁcant by the Mantel-Haenszel log-rank test. As
proportional hazards might not apply in this case, however,
the data were reanalyzed using the Gehan-Breslow-Wilcoxon
test, which does not rely on this assumption. The latter
analysis did reveal a signiﬁcant difference in median time to
diabetes onset (P  0.05). Following diabetes onset, progres-
sive hyperglycemia resulted in the development of polydipsia
at blood glucose concentrations of 25 mmol/l (Fig. 3A and
B). Since the upper limit of blood glucose measurement here
was 33 mmol/l, the maximum reported values are lower-limit
estimates of actual glucose concentrations in advanced
diabetes.
Most importantly, in tetracycline-treated hemizygous
animals, there was a signiﬁcant delay in disease progres-
sion following onset of hyperglycemia, as measured by
retardation in the rates of both blood glucose elevation
(Fig. 3A, P  0.01) and ﬂuid intake (Fig. 3B, P  0.01)
compared with water-treated transgenic animals. Tetracy-
cline had no effects on either blood glucose concentrations
or ﬂuid intake in nontransgenic littermates over the same
time period. We did not quantitate blood tetracycline
levels; however, assuming a similar bioavailability to oral
doxycycline or minocycline administered to mice (32), we
estimate that plasma tetracycline concentrations during
the polydipsic phase could reach low micromolar levels.
Survival analysis (Fig. 3C) showed that tetracycline-
treated transgenic animals had a signiﬁcantly increased
median survival (34%, P  0.05) for the period from
diabetes onset to death (155 days, n 
 17) compared with
the water-treated control group (116 days, n 
 19).
Examination of pancreata from terminally killed tetra-
cycline-treated animals also showed a positive correlation
between islet amyloid content and lifespan (Fig. 3D, P 
0.001, n 
 12, R
2 
 0.91). This ﬁnding was similar to that
observed for water-treated terminally diabetic hemizygous
mice wherein the corresponding regression slope was not
signiﬁcantly different (Fig. 1D). Interestingly, of all the
pancreata examined in this study the highest amyloid
content occurred in a tetracycline-treated mouse, a ﬁnding
consistent with the correspondingly increased lifespan
observed in this group.
Tetracycline (0.5 mg/ml drinking water) improved
glucose tolerance and delayed diabetes onset in
hemizygous animals (study 2). To investigate whether
the observed antidiabetes effects of tetracycline might be
attributable to potential indirect insulin-sensitizing effects,
parallel GTTs and ITTs were performed in independent
TABLE 1
Hormone concentrations in plasma and pancreatic tissue from fed wild-type (/) and hemizygous (
/) and homozygous (
/
)
hA/hIAPP transgenic mice at 30 days and 4 months of age
Plasma (pmol/l) Pancreas (pmol/mg)
Insulin Human amylin Murine amylin Insulin Human amylin Murine amylin
30 days
/ 186 	 39 (5) ND (5) 19.4 	 0.5* 798 	 69 (5) ND (4) 10.2 	 1.4 (5)

/ 157 	 26 (15) 40 	 4 (15) — 799 	 59 (15) 25 	 2 (15) —

/
 177 	 28 (5) 71 	 15† (5) — 221 	 55‡ (5) 12 	 5§ (5) —
4 months
/ 269 	 36 (12) ND (12) 17.5 	 1.3 (9) 1,261 	 142 (8) ND (9) 23.6 	 1.6 (9)

/ 238 	 36 (19) 42 	 5 (19) — 1,028 	 121(16) 28 	 3 (16) —
Data are means 	 SE. The ELISA assay used to measure hA/hIAPP has a reported 1% cross-reactivity with human insulin, glucagon,
glucagon-like peptide-1, pancreatic polypeptide, calcitonin, calcitonin gene–related peptide, and adrenomedullin and does not detectably
cross-react with mA/mIAPP (39). The in-house radioimmunoassay used to measure mA/mIAPP had 7% cross-reactivity with hA/hIAPP and
thus was used only in nontransgenic littermates. *Two pooled analyses representing a total of ﬁve animals. †P  0.05, two-tailed t test. ‡P 
0.001 vs. both groups, one-way ANOVA with Tukey’s post hoc test. §P  0.01, two-tailed t test. —, not determined; ND, not detected.
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treatment (Fig. 4). Hemizygous mice were administered
tetracycline in their drinking water from 30 days post-
weaning at 0.5 mg/ml to approximate the increased drug
intake observed during polydipsia in the previous study.
GTTs performed on a hemizygous cohort revealed no base-
line differences (0 days treatment; Fig. 4A) but signiﬁcantly
improved glucose tolerance in the tetracycline-treated mice
compared with water-treated controls at 30 days (Fig. 4B)
and 60 days treatment (Fig. 4C). Survival analysis indicated a
trend toward delayed diabetes onset in the tetracycline-
treated group (P 
 0.06, data not shown).
In a parallel study, a second independent hemizygous
cohort was treated with or without tetracycline immediately
postweaning. ITTs performed after 60 and 90 days treatment
showed that improved glucose tolerance was not due to any
insulin-sensitizing effect of tetracycline (Fig. 4D and E).
Tetracycline treatment also signiﬁcantly delayed the median
FIG. 2. Amyloid visualized by light microscopy was dissociable from occurrence of diabetes in hemizygous hA/hIAPP transgenic mice.
Photomicrographs show serial pancreatic islet sections from nontransgenic and human amylin transgenic animals. Left photomicrographs from
top three panels show insulin (green) and glucagon (red) immunoreactivity. Bottom two left photomicrographs show islet sections incubated
with antisera to somatostatin and glucagon revealing brown cytoplasmic staining. Middle and right panels show corresponding light- and
polarized-microscopic ﬁeld views of adjacent islet sections stained with Congo red. Amyloid birefringence is apple green, whereas that
corresponding to collagen is silvery. The scale bar (50 m) shown in top left photomicrograph applies to all images except for those
corresponding to the 600-day nondiabetic hemizygous mouse (second to bottom row), which represents 100 m. (A high-quality color digital
representation of this ﬁgure is available in the online issue.)
J.F. AITKEN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JANUARY 2010 165time to diabetes onset in this cohort of mice as compared
with the corresponding water-treated control group (Fig. 4F,
98 vs. 66 days, P  0.05). These studies showed that
improved glucose tolerance and delayed onset of diabetes in
tetracycline-treated hemizygous mice were not due to ex-
trapancreatic insulin-sensitizing actions or other putative
systemic effects of tetracycline on glucose homeostasis.
Amelioration of diabetes and increased lifespan by
tetracycline were dosage dependent (study 3). To
replicate and extend our previous ﬁndings, in particular
with regard to dosage-related effects, further groups of
hemizygous animals that had been administered water
from the time of weaning were randomly assigned at the
time of disease onset to one of the following groups:
water-only control (n 
 12), water containing 0.03 mg/ml
tetracycline (n 
 12) (study 3a, Fig. 5), or water containing
0.5 mg/ml tetracycline (n 
 10) (study 3b, Fig. 5). The
extent of suppression of disease progression in the tetra-
cycline-treated groups was dosage dependent with signif-
icant alleviation of hyperglycemia (P  0.01; Fig. 5A) and
corresponding ﬂuid intake (P  0.05; Fig. 5B) in the 0.5
mg/ml tetracycline–treated group compared with the wa-
ter-treated controls. The 0.5 mg/ml tetracycline–treated
group had a 254% increase in median survival from diabe-
tes onset to death compared with the water-treated con-
trol group (208 vs. 82 days, respectively, P  0.05; Fig. 5C),
and there was a signiﬁcant trend to dosage dependency
among the three groups (P  0.05).
Diabetes pathogenesis in hemizygous mice occurred
through islet -cell dysfunction followed by -cell
loss. To examine more precisely the effects of tetracycline
treatment on islet -cell mass, pancreatic islets were
examined in a further independent cohort of diabetic mice
studied at 6 weeks after disease onset. Hemizygous ani-
mals were randomly assigned at disease onset to one of
two groups: either water-treated control or treatment with
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FIG. 3. Chronic administration of tetracycline (0.03 mg/ml of drinking water) in hemizygous mice from the time of weaning ameliorated diabetes
and prolonged survival. Weekly blood glucose values (A) and ﬂuid intake (B) in tetracycline-treated () versus water-treated (control) (E)
animals. Each point represents the mean  SE of values derived from n  7–20 animals; (F, f): values for corresponding nontransgenic
littermates. Mean drug intake (mg  kg
1  day
1, mean  SD) per animal was calculated from weekly ﬂuid intake and weight measurements over
the phases of pre-diabetes (5.4  1, n  13), diabetes to polydipsia (4.4  0.7, n  16), and polydipsia to death (44  13, n  15). Body weights
at diabetes onset were also not signiﬁcantly different between the control and drug-treated groups. Following onset of polydipsia, the
tetracycline concentrations in the water of matched nontransgenic littermates were increased proportionately to maintain matched drug intake,
and no adverse effects on ﬂuid palatability were observed. Within the transgenic control group, 2 of 22 mice that spontaneously developed
diabetes were omitted from the ﬁnal analysis due to development of an eye infection and a tumor, respectively, whereas no animals were excluded
from the tetracycline-treated transgenic group. C: Percent survival from diabetes onset (, n  17; E, n  19). **P < 0.01; *P < 0.05. D:
Relationship between total area of amyloid deposits and lifespan in tetracycline-treated mice (P < 0.001, n  12, R
2  0.91).
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FIG. 4. Tetracycline (0.5 mg/ml of drinking water) improved glucose tolerance and delayed diabetes onset. Glucose tolerance tests were compared
between tetracycline-treated () and control water-treated (E) hemizygous mice at baseline (time  0) (A) and after 30 (B) and 60 (C) days
treatment. Statistical analysis by two-way ANOVA showed that curves corresponding to tetracycline-treated and control animals differed
signiﬁcantly after both 30 (P < 0.01) and 60 (P < 0.001) days treatment. Insulin tolerance tests were carried out in a second cohort of animals
after 60 (D) and 90 (E) days equivalent tetracycline treatment. Each point represents the means  SE of values derived from n  12–25 animals.
F: Survival analysis for the second cohort showed signiﬁcantly delayed diabetes onset in tetracycline-treated mice (n  18) versus the
water-treated control group (n  20). ***P < 0.01; *P < 0.05. In other experiments with nontransgenic littermates, glucose tolerance and insulin
tolerance tests performed at 0, 60, and 90 days treatment showed that tetracycline administration did not intrinsically affect glucose tolerance
or insulin sensitivity (not shown).
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3b. Interestingly, visual inspection of islets from hemizy-
gous mice with early- to mid-stage diabetes (Fig. 6A)
showed they were structurally well preserved, with insulin
areas similar to those of matched nontransgenic litter-
mates (Fig. 6B). Also, quantitative analyses of islet areas
revealed no signiﬁcant between-group difference at this
time-point (Fig. 6C). By contrast, animals with advanced
diabetes had comparatively elevated blood glucose con-
centrations and reduced insulin areas, consistent with islet
-cell loss (Fig. 6D).
These qualitative observations were conﬁrmed in an
exhaustive, quantitative blinded comparison of insulin
areas of 9–30 islets from individual tetracycline-treated
(Fig. 6E) and water-treated (Fig. 6F) hemizygous mice.
Although there was no signiﬁcant difference in mean
insulin area–to–islet area ratios between the two groups
(75 	 4%, n 
 8 vs. 71 	 7%, n 
 12, respectively), there
was a signiﬁcant difference in their variance (F test, P 

0.029), pointing to a between-group difference. This ﬁnding
was extended in further correlational analyses, which
showed that there were signiﬁcant inverse relationships
between blood glucose concentrations and mean islet
insulin area in each group (Fig. 6G). Here, there was a
signiﬁcant difference in the regression slopes between
tetracycline- and water-treated mice (Fig. 6G). In particu-
lar, insulin area–to–islet area ratios in diabetic hemizygous
mice, wherein blood glucose concentrations were 15
mmol/l, were comparable not only between tetracycline
and water-treated mice but also with values in nontrans-
genic nondiabetic mice, for example as represented by
mouse no. 352 (Fig. 6G, ).
We quantiﬁed pancreatic and serum insulin concentra-
tions by ELISA in further separate groups of hemizygous
mice 6 weeks after the onset of diabetes. Interestingly,
although some reduction in total pancreatic insulin con-
tent was evident in some animals, there was no apparent
relationship between insulin content and blood glucose
concentrations (Fig. 6H). Similarly, there was no evident
reduction in serum insulin concentrations, and indeed
some hemizygous animals displayed comparatively high
serum insulin concentrations during early diabetes (Fig.
6I). These ﬁndings showed that insulin area was main-
tained within the islets during early- and mid-stage diabe-
tes in hemizygous transgenic mice with no substantial
reductions in pancreatic insulin content or serum insulin
concentrations. They are consistent with islet -cell loss
as a correlate of later-stage, more severe diabetes (blood
glucose 15 mmol/l).
DISCUSSION
Our ﬁndings demonstrate that the amyloid deposits found
in the pancreatic islets of hA/hIAPP transgenic mice are
not intrinsically cytotoxic, an observation consistent with
the reported occurrence of islet amyloid in nondiabetic
humans (2). Perhaps most notably, amyloid deposition
was not observed in homozygous animals with severe,
early-onset diabetes but was present in both diabetic and
nondiabetic hemizygous animals, where it was positively
rather than negatively correlated with lifespan.
In homozygous transgenic animals, the lack of visible
amyloid deposition coupled with the higher intrinsic hA/
hIAPP expression and signiﬁcantly depleted pancreatic
insulin concentrations at the median time to diabetes
onset were all consistent with islet -cell loss as the major
diabetogenic mechanism. Evidence from other hA/hIAPP
transgenic murine lines has pointed to a role for soluble
oligomers in the increased frequency of -cell apoptosis in
late-stage diabetes (15,18,19). The corresponding lack of
amyloid in our homozygous mice is consistent with this
pathogenic mechanism and supports a growing body of
experimental data consistent with the hypothesis that
cytotoxic effects of preﬁbrillar aggregates of other amyloi-
dogenic proteins, such as -amyloid and -synuclein, can
elicit cell death (33–37).
Our ﬁndings also show that tetracycline can partially
suppress the progression of diabetes in hemizygous ani-
mals. In study 1, it slowed the rate of deterioration in
blood glucose and polydipsia after diabetes onset, com-
pared with matched control animals, which translated into
a 34% increase in median survival. By contrast, tetracy-
cline did not delay diabetes onset in this study, although
the lack of an effect may simply have reﬂected the
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FIG. 5. Suppression of diabetes progression by tetracycline treatment was dosage dependent. Tetracycline was administered to hemizygous
animals from the time of diabetes onset at concentrations of either 0.03 mg/ml () or 0.5 mg/ml () of drinking water and results compared with
those in water-treated control animals (E). Weekly blood glucose values (A) and ﬂuid intakes (B) are shown. Data are means  SE of values
derived from 6 to 12 animals per point. **P < 0.01; *P < 0.05 for the 0.5 mg/ml tetracycline-treated compared with water-treated control
hemizygous animals. C: Percent survival shown is in animals treated with 0.03 mg/ml tetracycline (n  12, P  0.08) or 0.5 mg/ml tetracycline (n 
10, P < 0.05) compared with those receiving water only (n  12). There was no signiﬁcant difference in bodyweight at diabetes onset or in the
median time to diabetes onset across all three diabetic groups, nor did tetracycline exert effects on bodyweight as indicated by similar growth
rates of tetracycline-treated and nontransgenic littermates. No animals were excluded from these analyses.
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phase. The likelihood that this explanation is correct was
conﬁrmed in study 2, wherein tetracycline administration
at the higher dosage of 0.5 mg/ml from 30 days after
weaning, signiﬁcantly delayed disease onset and progres-
sion. The observed improvement in glucose tolerance in
tetracycline-treated hemizygous mice after 30 and 60 days
of treatment is also consistent with observations from
FIG. 6. Quantitative islet immunohistochemistry indicates that -cell dysfunction preceded -cell loss in diabetic hemizygous mice. Pancreatic
islets were analyzed by blinded insulin histochemistry in hemizygous and matched nondiabetic control mice at time points that corresponded to
6 weeks after diabetes onset in each transgenic mouse. A: Insulin staining in a representative islet from a tetracycline-treated (0.5 mg/ml)
transgenic mouse (animal no. 351, /). B: An islet from its corresponding matched nontransgenic control (animal no. 352, /). C: Islet areas
did not differ signiﬁcantly between these two animals. By contrast, shown in D, is an islet from a hemizygous animal with markedly elevated blood
glucose accompanied by a decreased area of islet insulin staining. Scale bar represents 50 m. Quantitative analyses of insulin area–to–islet area
ratios from 9 to 30 islets per animal are shown in a series of individual tetracycline-treated (n  9) (E) or water-treated (n  12) (F) diabetic
hemizygous transgenic mice; each datum point represents the ratio from a single islet and horizontal lines are arithmetic means. For comparison,
islet analyses for animal no. 352, which is the tetracycline-treated nontransgenic and nondiabetic age-matched control for hemizygous animal no.
351, are shown in E as closed blue diamonds. G: Linear correlation analysis of the relationships between blood glucose values and insulin
area–to–islet area ratios were demonstrated in both groups (both P < 0.0001); there was also a signiﬁcant difference between the slopes of the
curves in the two groups (P < 0.0001); the solid blue diamond corresponds to the nontransgenic animal whose islet was shown in B. Blood glucose
and pancreatic insulin content (H) and serum insulin concentrations (I) in animals (n  3 replicates/mouse); these latter analyses were
performed in separate cohorts of water-treated (E) and tetracycline-treated (0.5 mg/ml, ) hemizygous mice studied at the time point 6 weeks
after diabetes onset. Data from matched nontransgenic and nondiabetic mice studied at the corresponding time point are indicated by closed
black symbols. Data in C, H, and I are means  SE. A, B, and D: BG, blood glucose. (A high-quality color digital representation of this ﬁgure is
available in the online issue.)
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mg/ml) but with administration from the time of disease
onset. In this study, tetracycline exerted a clear, dosage-
dependent effect to delay the deterioration in blood glu-
cose regulation and polydipsia, with the higher dosage
causing an increase in median survival of 254% in the
period following diabetes onset.
We found no evidence that the antidiabetes effects
evoked by tetracycline in the hemizygous mice were due
to any putative extrapancreatic effects, since ITTs re-
vealed that it exerted no detectable systemic insulin-
sensitizing effects in either hemizygous mice or their
nontransgenic littermates. Furthermore, tetracycline had
no measurable effects on glucose regulation in nontrans-
genic littermates. When taken together with the histolog-
ical analysis of islets 6 weeks after diabetes onset, these
data point toward preservation of islet -cell function as
the mechanism underlying tetracycline’s actions to delay
onset and progression of diabetes, possibly through inter-
actions with soluble nascent preﬁbrillar aggregates.
Finally, our ﬁndings show that -cell dysfunction and
not -cell loss was responsible for the initial development
of diabetes in these hemizygous mice. Compared with the
rapid onset and development of diabetes in homozygous
animals, diabetes onset and progression were signiﬁcantly
more gradual in the hemizygous group. Strikingly, non-
transgenic controls and hemizygous animals had similar
total pancreatic insulin content at the median time of
diabetes onset. Signiﬁcantly, their insulin areas were also
comparable in the early- and mid-stages of diabetes,
indicating that no signiﬁcant loss of -cells had ensued to
this point in disease progression. Direct measurements of
pancreatic and serum insulin concentrations 6 weeks
following diabetes onset, although variable, were also
consistent with the above ﬁnding, in that there were no
substantive reductions in insulin content and no clear
associations with blood glucose concentrations. This ef-
fect is consistent with the development of glucose blind-
ness in the islets of at least some hemizygous mice (38).
Our experimental analyses were clearly able to discrim-
inate a 20% loss in insulin staining area or in islet -cell
mass, but such absolute reductions only occurred in
association with advanced diabetes. That no signiﬁcant
reduction in insulin staining area occurred in early- to
mid-stage diabetes clearly demonstrates that hA/hIAPP
expression does not initially evoke diabetes in hemizygous
mice by eliciting overt islet -cell loss. In support of this
conclusion, extensive immunohistochemical analyses re-
vealed no evidence for -cell apoptosis in pancreatic
sections from hemizygous mice 6 weeks following diabe-
tes onset, as measured by caspase-3 or terminal deoxynu-
cleotidyl transferase-mediated dUTP nick-end labeling
staining (data not shown), although the assays we used
may have been insufﬁciently sensitive to detect rare apo-
ptotic cells in affected islets.
Our ﬁndings indicate that below a certain threshold,
hA/hIAPP expression causes islet -cell dysfunction lead-
ing to impaired insulin production, processing, and/or
secretion at the outset of diabetes (14). Here, we could not
investigate insulin processing due to the unavailability of
an appropriate mouse-speciﬁc proinsulin ELISA. As amy-
lin expression in our mice is under control of the rat
insulin 2 promoter, we expect that rising blood glucose
would establish a positive feedback cycle that progres-
sively facilitates islet -cell loss. Presumably, this latter
mechanism occurs by default in homozygous mice which
possess higher intrinsic hA/hIAPP expression.
In summary, our ﬁndings show that islet -cell dysfunc-
tion and not mature extracellular amyloid is the underpin-
ning cause for diabetes pathogenesis in hemizygous hA/
hIAPP transgenic mice. Moreover, deposition of micro-
scopically visible amyloid was positively correlated with
lifespan, showing that tissue hA/hIAPP deposits are not
intrinsically cytotoxic. Treatment with an effective dosage
of tetracycline delayed the onset and impeded the progres-
sion of diabetes in hemizygous mice. Consequently, any
intervention that allows progressive deposition of (appar-
ently benign) islet amyloid through mechanisms that re-
duce the cytotoxicity of preﬁbrillar aggregates might be
expected to prevent islet -cell degeneration.
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